SCHEMBL24601082

SCHEMBL24601082

CC(C)(C)OC(=O)NS(=O)(=O)NC1CCN(c2ccnc3[nH]c(=O)ccc23)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 1/20 0.40
SKP1 P63208 1/20 0.40
SKP2 Q13309 1/20 0.40
JAK1 P23458 4/20 0.37
JAK2 O60674 3/20 0.37
MAPK8 P45983 1/20 0.37
ATR Q13535 1/20 0.36
ATRIP Q8WXE1 1/20 0.36
ENPP1 P22413 2/20 0.36
CCNT1 O60563 1/20 0.36
CDK9 P50750 1/20 0.36
AKT2 P31751 1/20 0.35
BRS3 P32247 1/20 0.35
PIM1 P11309 1/20 0.35
PIM3 Q86V86 1/20 0.35
PIM2 Q9P1W9 1/20 0.35
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35
OPRK1 P41145 1/20 0.35
OGFRL1 Q5TC84 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29691669 1.00 CKS1B (0.40) CKS1BSKP1SKP2JAK1JAK2
SCHEMBL24600565 0.87 CKS1B (0.48) CKS1BSKP1SKP2JAK1JAK2
SCHEMBL29691572 0.87 CKS1B (0.48) CKS1BSKP1SKP2JAK1JAK2
SCHEMBL24600618 0.86 CA12 (0.40) CKS1BSKP1SKP2JAK1JAK2
SCHEMBL24601106 0.86 ENPP1 (0.41) CKS1BSKP1SKP2ENPP1CCNT1
SCHEMBL29248799 0.81 AKT2 (0.40) MAPK8ATRATRIPENPP1AKT2
SCHEMBL26679895 0.80 ATR (0.37) MAPK8ATRATRIPENPP1CDK9
SCHEMBL29691484 0.80 CKS1B (0.50) CKS1BSKP1SKP2JAK1JAK2
SCHEMBL24600959 0.80 CKS1B (0.50) CKS1BSKP1SKP2JAK1JAK2
SCHEMBL24601078 0.79 SIRT2 (0.47) CKS1BSKP1SKP2JAK1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240140944-A1 NOVEL NAPHTHYRIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE AND USE THEREOF TXINNO BIOSCIENCE INC. (KR) 2024-05-02 US disclosed
EP-4276100-A1 NOVEL NAPHTHYRIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE AND USE THEREOF Txinno Bioscience Inc. (KR) 2023-11-15 EP disclosed
WO-2022146022-A1 NOVEL NAPHTHYRIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE AND USE THEREOF 주식회사 티씨노바이오사이언스 2022-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240140944-A1 NOVEL NAPHTHYRIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE AND USE THEREOF ENPP1, ENPP3, ENTPD5 CKS1B 2081/4885SKP1 442/4885SKP2 3860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.